Compare AbbVie Inc (ABBV) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Huntington Bancshares Incorporated — how do they compare? AbbVie Inc trades at $252.5 (market cap $449.91B), while Huntington Bancshares Incorporated trades at $17.47 (market cap $36.50B). The key difference: AbbVie Inc is far larger — about 12.3× Huntington Bancshares Incorporated's market cap, and Huntington Bancshares Incorporated pays the higher dividend (3.44%). Which is the better fit depends on your goals.
| ABBV | HBAN | |
|---|---|---|
Market Cap | $449.91B | $36.50B |
Sector | Health | Financials |
52-Week High | $261.07 | $19.27 |
52-Week Low | $184.85 | $15.02 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | 3.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
Huntington Bancshares (HBAN) trades at $18.01, up 0.84% with bullish technical indicators and strong analyst support. The stock shows solid fundamentals with Q1 2026 EPS beating expectations at $0.26 vs. $0.23, revenue growth to $8.13B in 2025, and a reasonable P/E of 13.77. Recent news highlights successful Texas expansion and banking tech awards, while cash flow trends show consistent operational strength.
HBAN presents a compelling buy case with 51% analyst buy ratings and a $19.90 price target offering 10% upside. Key opportunities include M&A synergies and digital banking growth, though risks remain from integration challenges and competitive pressures in regional banking markets. The stock's current valuation and growth trajectory support a positive outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
